Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases.

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases.

Item
http://www.wikidata.org/entity/Q38368743
Matrigel induces L-plastin expression and promotes L-plastin-dependent invasion in human cholangiocarcinoma cells.Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a Chemical-Induced animal model.Klatskin-like lesions.Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Diagnostic and prognostic serum marker of cholangiocarcinoma (Review)Biomarkers in bile-complementing advanced endoscopic imaging in the diagnosis of indeterminate biliary strictures.Neutrophil gelatinase-associated lipocal in protein levels as an acute appendicitis biomarker in children.Institutional Experience in the Management of Hilar Liver Obstruction- A Series of 13 Cases.MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma.
P2860

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases.

Item
http://www.wikidata.org/entity/Q38368743
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Serum NGAL to Clinically Disti ...... Benign Biliary Tract Diseases.
@en
type
label
Serum NGAL to Clinically Disti ...... Benign Biliary Tract Diseases.
@en
prefLabel
Serum NGAL to Clinically Disti ...... Benign Biliary Tract Diseases.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Serum NGAL to Clinically Disti ...... Benign Biliary Tract Diseases.
@en
P2093
P2860
P304
P31
P356
P478
P577
P5875
P698
P921
P932